

# Global Presence, Deeply Engaged in Metabolic Diseases and Cancer Treatments

## COMPANY PROFILE

Established in 2013 and located in the Chengdu High-Tech Industrial Development Zone, with a registered capital of USD 70 million, covering a site area of over 45,000m<sup>2</sup>, and a completed construction area of approximately 30,000m<sup>2</sup>. Relying on the Group's R&D strengths in biopharmaceuticals and international standard quality systems, DesigneRx Pharmaceuticals has built advanced peptide drug production lines, equipped with bio-fermentation and chemical synthesis production platforms, with end-to-end capabilities from lab-scale to large-scale production. We are committed to the development and manufacturing of premium quality peptide drugs for the global market.

### Synthetic Peptides Solutions

DesigneRx Pharmaceuticals specializes in providing full-cycle peptide solutions from amino acid sequence design to Drug Substance (DS) or Active Pharmaceutical Ingredient (API), Finished Dosage Form(FDF).



### Biopharmaceutical Solutions

DesigneRx Pharmaceuticals is committed to providing comprehensive biopharmaceutical solutions for clients worldwide, from early-stage R&D to commercial production.



### Technical Advantages



**APIs**

GLP-1 Pipelines		
Name	Indication	DMF Filing
Semaglutide	Diabetes, Weight Management	2026.08
Tirzepatide	Diabetes, Weight Management	2027.12
Liraglutide	Diabetes, Weight Management	Under Development

**Finished Products**

Oncology Pipelines			
Name	Indication	Dosage form	IND Filing
Pegargiminase (ADI-PEG 20)	hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia	Inj	2026
Abemaciclib	early-stage breast cancer	Tab	Under Development
Olaparib	recurrent epithelial ovarian cancer, carcinoma of fallopian tube or primary peritoneal carcinoma	Tab	Under Development
Trilaciclib dihydrochloride	extensive-stage small cell lung cancer	Inj	Under Development

Non-oncology Pipelines			
Name	Indication	Dosage form	ANDA Filing
Semaglutide	Diabetes, Weight Management	Inj	2027
Liraglutide	Diabetes, Weight Management	Inj	Under Development
Tirzepatide	Diabetes, Weight Management	Inj	Under Development

· Synthetic Biology ·  
 · Intelligent Pharma ·  
 · Guarding Life ·  
 · Serving the World ·  
 · Creating the Future Together ·

**CONTACT INFORMATION**

-  **Tel** 86-28-87927676 ext. 826
-  **E-mail** business@polarispharma.com
-  **Website** www.polarispharma.com
-  **Address** Chengdu, China

**Official Account**

**WeChat**

**WhatsApp**
